Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT

NCT ID: NCT04519255

Last Updated: 2021-02-05

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-07-01
• Study Completion Date: 2023-07-31

Brief Summary

In this study, clinically cured patients with severe COVID-19 were used to evaluate the therapeutic effect of COVID-19 and the recovery and health status of patients over time with highly sensitive PET/CT imaging technology. At the same time, PET/CT whole body scan, dynamic imaging and mathematical dynamic model were combined to evaluate the functions of the heart, lung, liver, kidney, brain and other important organs and the outcome of inflammatory lesions in clinically cured COVID-19 patients.

Detailed Description

Covid-19 (Corona Virus Disease 2019, COVID-19), referred to as "COVID-19", refers to the pneumonia caused by novel Coronavirus 2019 (2019-NCOV/SARS-COV-2) infection. The clinical manifestations of the new patients were fever, fatigue and dry cough, while the symptoms of upper respiratory tract such as nasal congestion and runny nose were rare. Hypoxia occurs. About half of the patients developed dyspnea after one week, and in severe cases, the rapid progression was acute respiratory distress syndrome, septic shock, metabolic acidosis that was difficult to correct, and coagulation dysfunction. After the outbreak of COVID-19 in China, the National Health Commission issued the Diagnosis and Treatment Plan for COVID-19. By analyzing the epidemic situation and research progress, it organized experts to timely revise the diagnosis and treatment plan based on the analysis, study and summary of the previous medical treatment work.The discharge criteria for COVID-19 patients notified by the National Health Commission are remission of clinical symptoms, normal body temperature, normal CT, and negative nucleic acid tests for both tests. So far, the COVID-19 epidemic in China has been well under control. According to the latest statistics, 84,311 cases have been confirmed in total, and 1,433 cases have been confirmed so far.But studies (the latest from Dena Goffman's team, published in the NEJM) suggest that as many as 88 percent of coVID-19 patients are asymptomatic. Do cured patients leave the hospital with a percentage of asymptomatic patients?In addition, covid-19 cured patients in some regions turned positive again after discharge, indicating that long-term follow-up monitoring is of great significance for cured and discharged patients in addition to routine isolation observation!Moreover the literature at home and abroad other viral infections (such as hepatitis b, HIV, etc.) to cure patients found that the virus may lurk for a long time, the virus quantity contained in a very low level, the conventional detection method is difficult to detect, at the appropriate incentives can lead to attack, so for the new crown cure patients need close monitoring of systemic inflammation related lesions, and the situation of the latent virus.However, we still face many problems and challenges. For example, according to the latest data published by Dena Goffman's team in NEJM, the proportion of asymptomatic patients is as high as 88%, so the screening of asymptomatic patients is crucial.In many places, COVID-19 patients cured turn positive again after discharge. Therefore, it is of great significance to explore the mechanism of COVID-19 turning negative after discharge and evaluate the effect of novel Coronavirus and COVID-19 on patients' later recovery. Explore and develop more efficient and sensitive clinical detection methods to evaluate the treatment effect of covid-19 patients.

Positron emission computed tomography imaging technique is a nuclear medicine clinical diagnosis of advanced imaging techniques, can be shown on the in vivo biological molecules (such as 18 F- FDG, tracer nuclide labeled glucose molecules) metabolism, receptors and neurotransmitter activity of new functional imaging techniques, has been widely used in many kinds of disease diagnosis and differential diagnosis, a judgment, curative effect evaluation, viscera function research and development of new drugs, etc. Compared with traditional anatomical structure imaging, functional imaging PET has the following advantages: (1) High sensitivity. According to the test, PET molecular probe can pick up molecular events at the level of PM-NM in vivo. (2) High specificity, for the PET selected molecular probe, can only imaging the target molecules, for the same family of receptors, because the binding degree difference can be specifically distinguished; (3) Whole-body imaging, that is, one time PET imaging can obtain images of all regions of the whole body, and through the analysis can obtain the dynamic information of the metabolic changes of human tissues over time, which is of great significance for the research, prevention and evaluation of diseases.In particular, PET/CT scan provides a more reliable means of systemic monitoring for viruses that are lurking in all hidden parts of the body. (4) Security is good, although there are some radioactive nuclide PET need, but the amount of nuclide rarely used with short half-life, through two aspects of physical decay and biological metabolism function, in a very short time, client retention, a PET general inspection of radiation dose is far less than the conventional CT examination of a part, and safe and reliable.

Conditions

PET/CT; COVID-19; Respiratory Function; Inflammatory Lesions

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Screening of clinically cured patients with severe COVID-19

①Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age \> 18 years, age \< 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.

No interventions assigned to this group

Screening of clinically cured patients with mild COVID-19

①Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age \> 18 years, age \< 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.

No interventions assigned to this group

Healthy people who are not infected with COVID-19

① Volunteers who are not infected with COVID-19; ②Age \> 18 years, age \< 85 years, no gender restriction; ③ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ④ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

Screening of clinically cured patients with severe COVID-19:

• Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria;
• Age > 18 years, age < 85 years, no gender restriction;
• All had received COVID-19 drug therapy;
• ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min;
• Can obtain complete follow-up information, understand the situation of this study and sign informed consent.

Screening of clinically cured patients with mild COVID-19:

• Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria;
• Age > 18 years, age < 85 years, no gender restriction;
• All had received COVID-19 drug therapy;
• ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min;
• Can obtain complete follow-up information, understand the situation of this study and sign informed consent.

Exclusion Criteria

• Poorly controlled diabetics (fasting glucose level and GT;200 mg/dL);
• Any other malignancy within 5 years;
• Breastfeeding and/or pregnant women;
• Those who are prone to severe bleeding;
• Recent severe hemoptysis, severe cough, dyspnea or patients cannot cooperate;
• Severe emphysema, pulmonary congestion and pulmonary heart disease;
• The researchers believe that the subjects may not be able to complete the study or comply with the requirements of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hong Shan, Ph.D

Role: STUDY_CHAIR

Fifth Affiliated Hospital, Sun Yat-Sen University

Locations

Hongjun Jin

Zhuhai, Guangzhou, China

Countries

China

References

Yao J, Liu J, Bi L, Huang Y, Wang L, Zhang F, Wang Y, Jin H. The imaging quantification of multiple organs by dynamic 18F-FDG PET/CT in discharged COVID-19 patients: A prospective pilot study. Int J Med Sci. 2022 Sep 6;19(10):1539-1547. doi: 10.7150/ijms.73801. eCollection 2022.

Reference Type: DERIVED

PMID: 36185330 (View on PubMed)

Other Identifiers

ZDWY.FZYX.008

Identifier Type: -

Identifier Source: org_study_id